This week, MRC Clinical Trials Unit at UCL will be presenting the latest findings from some of our ongoing HIV and TB studies at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI).
CROI is an annual conference, which focuses on the latest research in the battle against HIV/AIDS and related infectious diseases. It will be attended by researchers and doctors from across the world, who will share the latest studies, important scientific developments and research methods.
This year, CROI will be running from Monday 13 February to Thursday 16 February, in Seattle, Washington.
Our research at CROI 2017:
Dr Jane Mallewa from Blantyre, Malawi has an oral presentation from the REALITY trial at CROI this year. REALITY is looking at whether we can reduce early mortality for people who start antiretroviral therapy (ART) with severe immunodeficiency.
The presentation, ‘A Randomized Trial of Ready-to-use Supplementary Food at ART Initiation in Africa’ will take place on Thursday 16 February, 11.45am to 12noon (local time). It will be in room 6c, as part of session O-10 (Improving the HIV Care Cascade). This is one of three randomisations from REALITY; the other two were presented as late breaker orals at the International AIDS conference in Durban last July 2016.
We also have some posters being presented at CROI 2017. Poster sessions take place at 2.30-4pm (local time). They all take place in the Poster Hall (4 E/F).